Surmodics (NASDAQ:SRDX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Surmodics (NASDAQ:SRDX) in a research note issued to investors on Monday. The brokerage issued a hold rating on the stock.

Other research analysts also recently issued research reports about the company. Lake Street Capital reaffirmed a hold rating and issued a $43.00 price objective on shares of Surmodics in a research note on Wednesday, May 29th. Needham & Company LLC reaffirmed a hold rating on shares of Surmodics in a research note on Monday, August 5th. Sidoti reaffirmed a neutral rating and issued a $43.00 price objective on shares of Surmodics in a research note on Wednesday, May 29th. Finally, Barrington Research reaffirmed a market perform rating on shares of Surmodics in a research note on Thursday, May 30th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $50.00.

Surmodics Stock Down 0.2 %

NASDAQ SRDX opened at $39.96 on Monday. The stock’s 50-day moving average price is $41.49 and its 200-day moving average price is $35.09. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a market capitalization of $570.23 million, a P/E ratio of 42.06 and a beta of 1.18.

Institutional Trading of Surmodics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hillsdale Investment Management Inc. grew its holdings in Surmodics by 15.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after buying an additional 620 shares in the last quarter. Hardin Capital Partners LLC purchased a new position in Surmodics during the 2nd quarter valued at approximately $206,000. SG Americas Securities LLC grew its holdings in Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Surmodics during the 2nd quarter valued at approximately $229,000. Finally, Lazard Asset Management LLC grew its holdings in Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after buying an additional 673 shares in the last quarter. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).